AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells

The research is part of a deal AstraZeneca formed with Ionis in 2015 to develop antisense therapies for metabolic, cardiovascular and renal diseases. In February of this year, AstraZeneca paid $30 milli https://www.fiercebiotech.com/research/astrazeneca-and-ionis-target-diabetes-antisense-approach-to-regenerating-pancreatic-cells